Considering the potential of PET imaging for precision medicine and drug development in
lung and other types of cancer, increasing efforts are warranted to standardize PET …

Molecular imaging (MI) may be defined as imaging in vivo using molecules that report on
biologic function. This review will focus on the clinical use of radioactive tracers …

PET using 68Ga-labeled fibroblast activation protein (FAP) inhibitors (FAPIs) holds high
potential for diagnostic imaging of various malignancies, including lung cancer (LC) …

Multimodality imaging can be a powerful tool for the simultaneous evaluation of both
anatomic and functional information and may potentially improve patient management …

Lung cancer is the leading cause of cancer mortality among both males and females
throughout the world. Worldwide, as many as one million people are affected by the disease …

Purpose Idiopathic pulmonary fibrosis (IPF) is a progressive disease with poor outcome and
limited therapeutic options. Imaging of IPF is limited to high-resolution computed …

Lung cancer remains a leading cause of cancerrelated deaths worldwide, accounting for
approximately 224,390 new patients and 158,080 deaths in 2016, according to the …

PET imaging of fluorodeoxyglucose (FDG) is one of several metabolic imaging procedures
being used to detect various diseases (1). FDG-PET imaging has been demonstrated to be …

Radiomics describes the extraction of multiple features from medical images, including
molecular imaging modalities, that with bioinformatic approaches, provide additional …

Cystic fibrosis (CF) is characterized by persistent neutrophilic lung inflammation that begins
early in life and leads to an inexorable progressive loss of lung function over time, causing …